Senzime’s Interim report January – March 2018

Uppsala, May 8, 2018. Senzime AB’s (publ) Interim report for January – March 2018 is now available on the company’s webbsite

“The beginning of 2018 has been characterized by a continued high pace, both in terms of sales and distribution agreements in new markets. The production set of the TetraGraph system is complete and sales have started. The level of interest in our products is high and we have already delivered some thirty systems. During the quarter, we have signed distribution agreements with new partners in Spain, Portugal, South Korea, and after the reporting period, also in Belgium, the Netherlands, Luxembourg, Austria, the Czech Republic and Slovakia. Together with earlier distribution agreements and the licensing agreement with Fukuda Denshi in Japan, we now have distribution agreements in 13 markets outside Sweden. We expect that distribution agreements for additional markets will be signed during the current year.” Says Lena Söderström, CEO of Senzime.

Financial information first quarter 2018

  •  Net sales amounts to KSEK 7 (0)
  •  Income after financial items amounts to KSEK -2,455 (-1,964).
  •  Earnings per share before dilution amounts to SEK -0.06 (-0.06).

For further information, please contact:

Jessica Roxhed, CFO

Tel: +46 703-94 94 98, e-mail: 


About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on May 8th 2018.

Explore our patient monitoring solutions

Get product details

How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.